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Abstract
Introduction: MicroRNAs (miRNAs) are a group of small noncoding RNAs involved in the regulation of gene
expression. As such, they regulate a large number of cellular pathways, and deregulation or altered expression of
miRNAs is associated with tumorigenesis. In the current study, we evaluated the feasibility and clinical utility of
circulating miRNAs as biomarkers for the detection and staging of breast cancer.
Methods: miRNAs were extracted from a set of 84 tissue samples from patients with breast cancer and eight
normal tissue samples obtained after breast-reductive surgery. After reverse transcription and preamplification, 768
miRNAs were profiled by using the TaqMan low-density arrays. After data normalization, unsupervised hierarchical
cluster analysis (UHCA) was used to investigate global differences in miRNA expression between cancerous and
normal samples. With fold-change analysis, the most discriminating miRNAs between both tissue types were
selected, and their expression was analyzed on serum samples from 20 healthy volunteers and 75 patients with
breast cancer, including 16 patients with untreated metastatic breast cancer. miRNAs were extracted from 200 μl of
serum, reverse transcribed, and analyzed in duplicate by using polymerase chain reaction (qRT-PCR).
Results: UHCA showed major differences in miRNA expression between tissue samples from patients with breast
cancer and tissue samples from breast-reductive surgery (P < 0.0001). Generally, miRNA expression in cancerous
samples tends to be repressed when compared with miRNA expression in healthy controls (P = 0.0685). The four
most discriminating miRNAs by fold-change (miR-215, miR-299-5p, miR-411, and miR-452) were selected for further
analysis on serum samples. All miRNAs at least tended to be differentially expressed between serum samples from
patients with cancer and serum samples from healthy controls (miR-215, P = 0.094; miR-299-5P, P = 0.019; miR-411,
P = 0.002; and miR-452, P = 0.092). For all these miRNAs, except for miR-452, the greatest difference in expression
was observed between serum samples from healthy volunteers and serum samples from untreated patients with
metastatic breast cancer.
Conclusions: Our study provides a basis for the establishment of miRNAs as biomarkers for the detection and
eventually staging of breast cancer through blood-borne testing. We identified and tested a set of putative
biomarkers of breast cancer and demonstrated that altered levels of these miRNAs in serum from patients with
breast cancer are particularly associated with the presence of metastatic disease.
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Introduction
MicroRNAs (miRNAs) are a group of small (20 to 25
nt) noncoding RNAs able to regulate gene expression
posttranscriptionally by binding to the 3’-untranslated
region (UTR) of target mRNAs [1-3]. Since the initial
discovery in Caenorhabditis elegans, more than 1,000
human miRNAs have been described, each of them tar-
geting about 100 different mRNA molecules [4-6]. In
this way, approximately 30% of all human genes are
regulated by miRNAs [7,8], thereby influencing several
different pathways and processes in the cell, including
development, differentiation, apoptosis, and cell prolif-
eration [9-11].
As miRNAs are involved in fine-tuning gene expres-
sion in the cell [1,2], deregulation of miRNA expression
could lead to altered gene expression, which might con-
tribute to the development of cancer [12]. Several stu-
dies have shown a differential miRNA-expression profile
in cancer as compared with normal controls [13-15].
Although specific miRNAs can be upregulated in cancer
[16], global miRNA downregulation is a common trait
of human malignancies [13,17]. Furthermore, miRNAs
are involved in the metastatic cascade, which is the
most dismal feature of tumor biology with respect to
patient prognosis.
MiRNA-expression profiling of primary tumor sam-
ples and their associated metastases identified both pro-
metastatic and metastasis-suppressor miRNAs [15].
These miRNAs modulate the expression of metastasis-
associated genes [18,19], both directly and indirectly, by
influencing the epigenetic machinery [20].
Breast cancer is the most frequent carcinoma and the
second most common cause of cancer-related mortality
in women [21]. In the past decade, it has been repeat-
edly shown that breast cancer is a heterogeneous condi-
tion consisting of at least five [22] but possibly more
[23,24] molecular subtypes. These molecular subtypes
(Luminal A, Luminal B, Basal-like, ErbB2+, and Normal-
like) are characterized by specific mRNA-expression
profiles. Blenkiron and colleagues [14] showed that
these specific mRNA-expression profiles are at least par-
tially attributable to differential miRNA expression.
Also, Iorio and colleagues [25] identified a global pattern
of miRNA deregulation in breast cancer tissue when
compared with normal breast tissue, hinting at the
importance of miRNA deregulation in the development
of breast cancer in general.
As miRNAs appear to be critical regulators of tumor
biology, their potential as prognostic and predictive bio-
markers has recently been given attention. In addition,
their great stability when compared with mRNA mole-
cules, both in blood samples and in formalin-fixed, paraf-
fin-embedded tissue samples, offers a great advantage
[26,27]. Levels of miRNAs do not substantially change
when serum or plasma samples are subjected to freeze-
thaw cycles, boiling, or maintenance at room temperature
[28,29]. As the bloodstream is easily accessible, blood-
borne miRNAs or circulating miRNAs hold the potential
to serve as noninvasive biomarkers in oncology.
Recently, Heneghan and colleagues [30] showed that
miRNA expression is detectable in whole blood, plasma,
and the serum of cancer patients and healthy controls.
In addition, miRNA-195 was identified as a potential
biomarker for detecting noninvasive and early-stage
breast disease [30].
The goal of this study was twofold. First, we aimed to
identify patterns of miRNA deregulation in breast can-
cer. Therefore, we compare miRNA-expression patterns
between breast tumor samples classified according to
the molecular subtypes and between breast tumor sam-
ples and normal breast samples. We hypothesize that
such profiles can be informative for breast cancer detec-
tion and prognosis and might assist in defining specific
targets for future therapy.
Second, we investigated whether the expression levels
of miRNAs are measurable in blood samples from
patients with breast cancer and healthy volunteers and if
such expression profiles are potentially useful for the
detection and staging of breast cancer.
Materials and methods
Patients and samples collection
Tumor and blood samples were obtained from patients
with breast adenocarcinoma treated in the Breast Clinic
of the General Hospital Sint-Augustinus (Antwerp, Bel-
gium). Tissue and serum samples were derived from
two entirely independent populations. Each patient gave
written informed consent. This study was approved by
the Institutional Review Board. Clinicopathologic data
are stored in a database in accordance with hospital
privacy rules and are summarized in Table 1. All tissue
samples were stored in liquid nitrogen within 15 min-
utes after excision (median delay of 9 minutes). Healthy
control tissue was obtained from breast-reductive sur-
gery. None of the control samples showed pathologic
changes. In total, 84 tumor samples and eight healthy
control samples were included.
The collection of serum samples was described pre-
viously [31]. In brief, samples were prospectively obtained
from 75 patients with breast cancer and 20 healthy volun-
teers. Patients were divided into three groups: four patients
with localized breast cancer (group A), 55 patients with
metastatic breast cancer receiving treatment (group B), and
16 patients with untreated metastatic breast cancer (group
C). The blood samples of patients with metastatic disease
were taken during the course of treatment. For all these
van Schooneveld et al. Breast Cancer Research 2012, 14:R34
http://breast-cancer-research.com/content/14/1/R34
Page 2 of 16
samples, circulating tumor cells (CTCs) were enumerated
by using the CellSearch system (Veridex, Warren, NJ,
USA), CK19, and mammaglobin mRNA expression was
recorded, the ADNAgen test for detection of CTCs was
performed, and levels of total plasma DNA and serum
methylated DNA for ESR1, RASSF1A, or APC1 were mea-
sured in earlier studies [31,32]. Disease status was assessed
by using the RECIST (Response Evaluation Criteria in
Solid Tumors) criteria without knowledge of the patient’s
CTC or circulating DNA results [33]. Stable disease was
measured up to 8 weeks after the initiation of therapy. In
addition, we collected blood samples from an additional
series of 18 unselected patients to evaluate which blood
medium (that is, serum, plasma, platelet-rich plasma,
whole blood, or peripheral blood mononuclear cells
(PBMCs)) was best suited for extraction of small RNAs
(sRNAs).
RNA extraction, cDNA synthesis, and miRNA
quantification for tissue samples
After tissue disruption, total RNA was extracted by
using the mirVana miRNA Isolation Kit (Ambion, Aus-
tin, TX, USA) according to the manufacturer’s
instructions for total RNA isolation. In brief, the sample
was homogenized in a denaturing lysis solution, fol-
lowed by an acid-phenol:chloroform extraction. There-
after, the sample was purified on a glass-fiber filter and
quantified by using the Nanodrop ND1000 (NanoDrop
Technologies, Waltham, MA, USA). Total RNA (100
ng) was converted to cDNA by priming with two pools
of stem-looped RT primers (Megaplex RT Primers,
Human Pool A & B; Applied Biosystems, Foster City,
CA, USA) in combination with the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems), allowing
the simultaneous transcription of 377 unique miRNAs
and six endogenous controls per primer pool. In brief, 3
μl of total RNA was supplemented with RT primer mix
(×10), dNTPs with dTTP (100 mM), Multiscribe Reverse
Transcriptase (50 U/μl), RT buffer (×10), MgCl2 (25
mM), and RNase inhibitor (20U/μl) in a total reaction
volume of 7.5 μl.
Thermal-cycling conditions were as follows: 40 cycles
at 16°C for 2 minutes, 42°C for 1 minute, and 50°C for
1 second, followed by reverse transcriptase inactivation
at 85°C for 5 minutes. The Megaplex RT product (2.5
μl) was preamplified by using the TaqMan PreAmp
Master Mix (Applied Biosystems) and preamplification
primers in a 25-μl PCR reaction. For each pool of stem-
looped RT primers in the cDNA reaction, a different
pool of PreAmp Primers (Human Pool A & B; Applied
Biosystems) was used. Thermal-cycling conditions were
as follows: 95°C for 10 minutes, 55°C for 2 minutes, and
75°C for 2 minutes, followed by 12 cycles of 95°C for 15
seconds and 60°C for 4 minutes. MiRNA quantification
was performed with the TaqMan Human MicroRNA
Array sets A & B (Applied Biosystems), each containing
384 TaqMan miRNA assays. The PreAmp product was
diluted fourfold. Each of the eight wells was loaded with
100 μl of PCR reaction mix, containing 50 μl of Taq-
Man Universal PCR Master Mix, no AmpErase uracil
N-glycosylase (UNG) (Applied Biosystems), 1 μl of
diluted PreAmp product, and 49 μl of nuclease-free
water. Thermal-cycling conditions were as follows: 94.5°
C for 10 minutes, followed by 40 cycles at 97°C for 30
seconds and 59.7°C for 1 minute. All PCR reactions
were performed on a 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems).
To test the efficiency of the miRNA assays, we com-
pared the Ct-values of an undiluted sample with those
of a 10-fold diluted sample. To evaluate the linearity of
the preamplification, we compared the Ct-values of all
miRNAs on both array cards for one sample before and
after preamplification. The reproducibility of the arrays
was tested by analyzing four samples in duplicate. The
robustness of the TaqMan RT-PCR method was investi-
gated by comparing the qRT-PCR miRNA expression
profile of 12 samples with their miRNA expression
Table 1 Clinicopathologic data
Parameter Group Tissue (n = 84) Serum (n = 75)
T status 1 27 (32%) 31 (41%)
2 27 (32%) 22 (29%)
3 6 (7%) 4 (5%)
4 24 (29%) 18 (25%)
N status 0 35 (42%) 28 (37%)
1 21 (25%) 15 (20%)
2 14 (17%) 10 (13%)
3 13 (15%) 9 (12%)
4 1 (1%) 13 (18%)
M status 0 70 (83%) 4 (5%)
1 14 (17%) 71 (95%)
ER status Negative 25 (30%) 23 (31%)
Positive 59 (70%) 52 (69%)
PR status Negative 45 (54%) 36 (48%)
Positive 39 (46%) 39 (52%)
ErbB2 status Negative 62 (74%) 49 (65%)
Positive 22 (26%) 26 (35%)
Grade 1 9 (11%) 14 (19%)
2 32 (38%) 29 (39%)
3 43 (51%) 32 (42%)
Stage I 24 (29%) 19 (25%)
II 20 (24%) 14 (19%)
III 27 (32%) 22 (29%)
IV 13 (15%) 20 (27%)
Disease status Progressive 29 (35%) 47 (63%)
Nonprogressive 55 (65%) 28 (37%)
ErbB2 status is determined by using the Hercep test with confirmation by
FISH. Disease status is determined by using the RECIST criteria.
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profile obtained by using the nCounter Analysis System
(Nanostring Technologies, Seattle, WA, USA). This sys-
tem is a medium-high throughput gene-expression
quantification system with PCR sensitivity that uses a
novel digital technology based on direct multiplexed
measurement of miRNA expression. Besides a direct
quantification, the workflow incorporates only one enzy-
matic step (ligase step to enable tagging of the miRNAs)
instead of three enzymatic steps in the qRT-PCR work-
flow, thereby substantially reducing the possibility for
technical bias. The nCounter experiment was performed
in collaboration with the VIB MicroArray Facility
(O&N, UZ Gasthuisberg, Leuven, Belgium).
RNA extraction, cDNA synthesis, and miRNA
quantification for blood samples
First, we evaluated which blood medium was best suited
for the extraction of sRNA molecules. Therefore,
plasma, platelet-rich plasma, serum, whole blood, and
PBMCs were obtained from 18 patients with breast can-
cer. Peripheral blood was collected in a 9-ml EDTA
tube, from which 3 ml of whole blood was transferred
into a cryovial while the remaining blood was centri-
fuged slowly (150 g, 20 minutes) at 4°C to generate pla-
telet-rich plasma. Plasma and PBMCs were obtained in
an 8-ml CPT tube, which was centrifuged (1,650 g, 20
minutes) at room temperature. Plasma and PBMC ali-
quots were transferred into separate cryovials. Finally, 8
ml blood was collected in serum separator tubes (Becton
Dickinson, Franklin Lakes, NJ, USA) and centrifuged
(2,000 g, 10 minutes) at room temperature. All samples
were stored at -80°C until use.
sRNA was isolated from 200 μl of each medium by
using the microRNA Isolation Kit (BioChain Institute
Inc, Hayward, CA, USA) according to the manufac-
turer’s instruction for sRNA purification. In brief, after
adding lysis buffer to the sample for homogenization, 20
μl of Proteinase K solution (Qiagen, Valencia, CA, USA)
was added and incubated for 10 minutes at 75°C to
digest the excess of proteins released after addition of
the lysis buffer. This was followed by an acid-phenol:
chloroform extraction. Small and large RNAs were sepa-
rated by using a centrifugation step, after which the
large RNAs were retained on a glass-fiber filter. The
sRNA molecules were recovered from the flow-through
by purifying them on a second glass-fiber filter, and
their concentration and purity (A260/A280 and A260/
A230) was recorded by using the NanoDrop ND1000
(NanoDrop Technologies, Waltham, MA, USA). The
concentrations were compared by using a Kruskal-
Wallis test with Tukey HSD post hoc testing.
To evaluate circulating miRNA expression in blood
samples from 20 healthy volunteers and 75 patients with
breast cancer, we isolated total RNA, as described
before. Isolated total RNA was reverse transcribed to
produce cDNA by using the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems) by prim-
ing with TaqMan MicroRNA Assays (Applied Biosys-
tems) directed at 4 miRNAs identified by comparing
tumor tissue with normal breast tissue (vide supra). In
addition, miR-16 expression was determined as a nor-
malization factor. In brief, each 15-μl reaction contained
0.15 μl 100 mM dNTPs with dTTP, 1.0 μl Multiscribe
Reverse Transcriptase (50 U/μl), 1.50 μl RT Buffer
(×10), 0.19 μl RNase Inhibitor (20 U/μl), 4.16 μl nucle-
ase-free water, 5.0 μl total RNA, and 3.0 μl RT primer.
Thermal-cycling conditions were 30 minutes at 16°C, 30
minutes at 42°C, and 5 minutes at 85°C. Each 20-μl
reaction for the real-time quantitative PCR contained
1.0 μl real-time primer, 1.33 μl product from RT reac-
tion, 10.0 μl TaqMan Universal PCR Master Mix, no
AmpErase UNG (Applied Biosystems), and 7.67 μl
nuclease-free water. The reactions were performed in
duplicate on a 7900HT Fast Real-Time PCR System in
the 9600 emulation mode, with conditions of 10 min-
utes at 95°C, followed by 40 cycles of 15 seconds at 95°
C and 1 minute at 60°C. The mirVana miRNA Refer-
ence Panel (Ambion, Austin, TX, USA) was included in
each PCR plate in a 2,000-fold dilution to correct for
between-plate differences.
Statistics and bioinformatics
All subsequent analyses were performed by using Bio-
Conductor in R. To reduce technical variation, the
miRNA assays with a PCR efficiency outside the range
of 2log(10) or 3.32 ± 25% [34] and those with Ct values
above 35 in at least 25% of the cases were filtered out.
By using efficient and informative miRNA assays only,
we calculated the mean difference between the Ct values
of one sample before and after preamplification. To
avoid technical bias, we excluded miRNA assays with a
difference in Ct values before and after preamplification
outside the range of the mean value ± 25%. For the final
set of miRNAs, we calculated the mean expression level
per sample and used this value as a normalization factor
to account for differences in input material [35]. Relative
miRNA expression levels were calculated by using the
ΔCt-method [36] and log2-transformed to obtain a nor-
mal distribution. To investigate assay reproducibility, we
correlated the expression profiles of the duplicate sam-
ples by using the Spearman correlation coefficient.
An additional technical validation was done by per-
forming a pairwise correlation analysis between the
miRNA profiles obtained by qRT-PCR and the nCounter
Analysis System for the 12 samples analyzed on both
platforms. Both correlation analyses were done by using
the normalized expression profiles of the 327 common
miRNAs only.
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Unsupervised hierarchical cluster analysis (UHCA),
with the Manhattan distance as similarity metric and
Ward clustering as the dendrogram drawing method,
was performed to visualize global themes in the expres-
sion data. We classified samples according to the
miRNA-centroids for molecular subtypes published by
Blenkiron et al. [14]. Therefore, we correlated the mole-
cular subtype-specific miRNA-expression profiles of
each sample with each of the five miRNA-based expres-
sion centroids by using the Spearman correlation
coefficient.
The resulting classification was compared with the
UHCA result. For 66 samples with available Affymetrix-
profiles, we compared the correlation coefficients
between the samples grouped according to the SSP (sin-
gle-sample predictor)-defined molecular subtype classifi-
cation [37] obtained through mRNA-expression
profiling reported in earlier studies [38,39]. Significance
was assessed by using the Mann-Whitney U tests.
Next, we aimed to identify molecular subtype-specific
miRNAs. Therefore, we performed a pairwise compari-
son of the different molecular subtypes, defined through
mRNA-expression profiling, by using regression analysis
with the limma-package. False Discovery Rate (FDR)
correction was performed by using the Benjamini and
Hochberg step-up procedure. For each subtype, we
crossed the lists of differentially expressed miRNAs
resulting from the pairwise comparisons involving the
desired subtype in search for common miRNAs.
By using regression analysis, we identified differentially
expressed miRNAs between normal and tumor samples.
Resulting P values were corrected for false discovery, as
described earlier. To investigate global over- or underex-
pression in normal samples, we calculated the median
expression level of the differentially expressed miRNAs
per sample. These median expression values were com-
pared by using Mann-Whitney U testing. The top four
differentially expressed miRNAs by fold-change were
selected for further analysis. For these miRNAs, we
identified target mRNAs in at least two of three public
databases (PicTar, TargetScan, and Miranda) by using
the RmiR-package. These target-gene lists were sub-
jected to Ingenuity Pathway Analysis (IPA) to study the
implications of the identified miRNAs in cancer biology.
Expression levels of circulating miRNAs were calcu-
lated with miR-16 as normalization factor. Raw Ct
values measured in the miRNA Reference Panel were
subtracted from the Ct values measured in the samples,
yielding a between-plate corrected expression value for
each miRNA per 200 μl of serum. The miR-16 normal-
ized expression value was calculated by subtracting the
between-plate corrected expression value for miR-16
from the between-plate corrected expression values for
the remaining miRNAs (ΔΔCt-method). Relative
expression values were calculated by using the 2-ΔΔCt
method [36]. To compare the expression data with cate-
goric variables, the Mann-Whitney U test was per-
formed. To compare expression data with continuous
variables, Spearman correlation coefficients were
calculated.
Results
Technical validation of miRNA profiling in tissue samples
First, we excluded 292 miRNA assays (A panel, 83; B
panel, 209) with a Ct value above 35 in at least 25% of
the samples, leading to 462 informative miRNAs (A
panel, 294; B panel, 168). Before performing the data
normalization, we checked the PCR efficiencies of all
miRNA assays on the array cards by performing a 10-
fold dilution series and subtracting the Ct values of the
undiluted sample from the Ct values of the diluted sam-
ple. Theoretically, for an efficient PCR reaction, this dif-
ference should equal 2log(10) or 3.32. We excluded 23
(A panel, 14; B panel, 9) miRNA assays with PCR-effi-
ciencies outside the range of 3.32 ± 25%. The distribu-
tion of the PCR efficiencies and the cut-off values for
exclusion are shown in Figure 1A.
Next we evaluated the linearity of the preamplification
by comparing the miRNA-expression profiles of a sam-
ple before and after preamplification. This analysis was
done for 439 miRNAs that remained after exclusion of
noninformative and inefficient miRNA assays. The mean
difference between the Ct values before and after pre-
amplification was 8, and miRNA assays with a difference
in Ct value outside the range of 8 ± 25% were excluded
from further analysis (A panel, 30; B panel, 36). As
such, the final data set consisted of 373 miRNAs that
were normalized by using the ΔCt method with the
median Ct value per sample as normalization factor.
The scatterplot comparing the Ct values for those 373
miRNAs before and after preamplification is shown in
Figure 1B, and regression analysis demonstrated a signif-
icant and linear relation (R2 = 0.927; P < 0.001).
Next, we investigated the effect of profiling miRNA
expression by using two different array cards (A and B)
per sample. Therefore, UHCA was performed on the
normalized miRNA expression data, and the result is
shown in Figure 2. The cluster pattern of the miRNAs,
represented by the dendrogram in the Y-axis, reveals
that the assays allocated at different array cards are not
segregated. In addition, miRNA assays directed at differ-
ent isoforms of the same miRNA and represented on
different array cards cluster on terminal branches in
approximately 80% of the cases. These data indicate that
variation in miRNA expression related to the incorpora-
tion of two separate assays per sample is minor.
Finally, we evaluated the reproducibility of the miRNA
assays. Therefore, we analyzed four samples in duplicate
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and compared their normalized miRNA expression pro-
files. A representative scatterplot is show in Figure 1C,
and all scatterplots are shown in Additional file 1.
Spearman correlation coefficients ranged from 0.98 to
0.99 (all P values < 0.001), indicating good assay
reproducibility.
Next, we analyzed the miRNA expression profiles of
12 samples by using the nCounter Analysis System and
compared them with the normalized expression data
obtained through qRT-PCR. The Spearman correlation
coefficients ranged from 0.63 to 0.75 with a median
value of 0.72 (all P values < 0.001). Scatterplots for all
comparisons are shown in Additional file 2, and a repre-
sentative scatterplot is provided in Figure 1D.
Overall, our data indicate that technical variation in
expression for the panel of 373 miRNAs is minor.
miRNA expression profiling of breast tumor and normal
breast samples
With the miRNA centroids for molecular-subtype classi-
fication [14], we classified the 84 breast cancer tissue
samples and eight normal tissue samples in our data set.
18, 15, 15, 19, and 25 samples were classified as Basal-
like, ErbB2+, Luminal A, Luminal B, and Normal-like,
respectively. The classification result is shown under the
dendrogram in Figure 2. We observed a significant (P <
0.001) agreement between the miRNA-based molecular
subtype classification and the clustering pattern of the
 
 
Figure 1 The distribution of polymerase chain reaction (PCR) efficiencies, calculated as the differences between the Ct values of
undiluted sample and the Ct values of a 10-fold diluted sample. (A) Theoretically, this difference should equal 3.32 or 2log(10). All miRNA
assays with a difference in Ct value between 3.32% and 25% were included for further analysis. A blue dashed line indicates the boundaries of
the interval; a blue solid line indicates the theoretical expected value of 3.32. To account for differences in preamplification, we compared the Ct
values of a sample before and after preamplification. The median difference in Ct value was 8, and all miRNA assays with a difference of 8% ±
25% were included for further analysis. The scatterplot in (B) demonstrates an almost perfect linear relation for those selected miRNAs before
and after preamplification. The blue line represents the regression line, for which the equation is given on top of the scatterplot. To evaluate
assay reproducibility, we tested four samples in duplicate. The scatterplot in (C) demonstrates the result for one of these samples. The blue line
represents the regression line, and the correlation coefficient resulting from the comparison of both profiles is given on top of the scatterplot.
Further technical validation of our miRNA-expression data was performed for 12 samples by analyzing their miRNA-expression profile with the
nCounter Analysis System and comparing this result with the qRT-PCR-based miRNA-expression profile. The scatterplot in (D) demonstrates the
result for one of these samples. The blue line represents the regression line, and the correlation coefficient resulting from the comparison of
both profiles is given on top of the scatterplot.
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tissue samples after UHCA. Downstream of the first
bifurcation, we observe a cluster composed of 76% of
Normal-like samples, which was further divided into
two clusters separating the Normal-like tumor samples
from the normal breast samples. Further division of the
dendrogram yielded a cluster composed of 77% of
Basal-like samples and a cluster enriched for Luminal
samples (that is, 89% of the samples classify as Luminal
A or Luminal B). In addition, 60% of the ErbB2+ sam-
ples fell into one sample cluster. Interestingly, down-
stream of the third bifurcation, we observed a sample
cluster not enriched for any of the molecular subtypes
(Luminal A, 3; Luminal B, 4; ErbB2+, 3; and Normal-
like, 1). Given the hierarchy of the dendrogram, this
Figure 2 Heatmap showing the result of an UHCA (Manhattan distance, Ward linkage) for all 373 miRNAs in all 92 samples. The
miRNA-expression data are represented in matrix format, with rows indicating miRNAs and columns indicating samples. Overexpressed miRNAs
are color-coded red, and repressed miRNAs are color-coded green. Color saturation indicates the level of overexpression. Six samples clusters
could be discerned based on miRNA-expression differences, indicated by alternating blue and grey colors in the dendrogram. Underneath the
sample dendrogram, the molecular-subtype classification is indicated (red, Basal-like; orange, ErbB2+; green, Luminal A; blue, Luminal B; gray,
Normal-like). The true-normal breast samples are indicated by a darker shade of gray. The colored bar to the side of the heatmap indicates the
array card to which the corresponding assay is allocated (red, A; blue, B).
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sample cluster may well represent a novel miRNA-based
breast cancer subtype. Overexpressed miRNAs in this
sample group are known for their tumor-suppressive
roles in (breast) cancer: the miR-200 family (miR-200a,
miR-200b, miR-200c, and miR-141), the let-7 family
(let-7a, let-7f, and let-7g), and NFB-regulating miRNAs
(miR-146a and miR-155).
For 66 of 92 samples, Affymetrix mRNA expression
profiles were obtained in previous studies [38,39]. Clas-
sification of these samples according to the SSP-algo-
rithm yielded an agreement of 66% with the
classification according to the miRNA centroids. Sub-
type-specific correlation coefficients were compared
between the SSP-defined molecular subtypes, and results
are shown in Figure 3. For all comparisons, the subtype-
specific correlation coefficients obtained by using the
miRNA-centroids were significantly elevated in the
group of samples classified in the corresponding subtype
by using mRNA data (all P values < 0.05). When dichot-
omizing the Spearman correlation coefficients per sub-
type relative to 0, we observed an average classification
error rate of 36%, with the highest and lowest classifica-
tion error rates observed for the Luminal B and ErbB2+
samples (44% and 27%), respectively.
To identify subtype-specific miRNAs, we performed
pairwise comparisons between tumor samples grouped
by the SSP-defined molecular subtypes. The results are
summarized in Table 2. At a P-value cut-off level of
0.01 (maximal FDR of 15%), we identified 16, 0, 2, 3,
and 40 miRNAs specific for the Basal-like, ErbB2+,
Luminal A, Luminal B, and Normal-like subtypes,
respectively. Comparison of these results with the
expression data published by Blenkiron and colleagues
[14] revealed remarkably similar expression patterns for
several key miRNAs. For example, miR-135b and miR-
106a are upregulated in Basal-like breast cancers in both
studies. Also, miR-100 and miR-145 show comparable
expression patterns in both studies, with elevated
expression in the Normal-like and Luminal samples.
Detailed results are provided in Additional file 3.
Finally, we compared the miRNA expression profiles
of tumor samples with the normal breast samples
obtained after breast-reductive surgery. As reported ear-
lier, the clustering pattern of the tissue samples (Figure
2) suggests major differences in miRNA expression
between the tumor samples and normal breast samples.
We identified 59 differentially expressed miRNAs at an
FDR less than 1%. The median expression value of these
miRNA per sample was significantly higher in normal
breast samples (Normal, 1.542; Tumor, 0.024; P <
0.001). Data are presented in boxplot format in Figure
4A. The top four miRNAs by fold-change (miR-299-5p,
miR-215, miR-411, and miR-452) were selected as
potential biomarkers for breast cancer detection (Figure
4B through 4E). With the RmiR-package, we identified
611, 715, 575, and 1,863 mRNA targets for the set of
Figure 3 Comparison of the mRNA-based molecular subtype classification by using the SSP method with the miRNA-based
classification by using the expression centroids reported by Blenkiron and colleagues. This analysis was performed only for those samples
for which Affymetrix mRNA-expression profiles are available (N = 66). The SSP-classification is provided in the X-axis (B, Basal; E, ErbB2+; LA,
Luminal A; LB, Luminal B; N, Normal-like; and R, Rest). The Spearman correlation coefficients resulting from the miRNA-based molecular subtype
classification are indicated in the Y-axis. For each miRNA-based molecular subtype-specific centroid and each sample in our data set, the
Spearman correlation coefficients were determined. The molecular subtype-specific correlation coefficients were statistically compared between
samples belonging to and not belonging to the SSP-defined molecular subtype of interest. P values are indicated under the corresponding
boxplots.
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Table 2 Identification of subtype-specific miRNAs
Subtype Comparator Number Common
Basal-like ErbB2+ 26 hsa-miR-135b#, hsa-miR-135b, hsa-miR-934, hsa-miR-577, hsa-miR-501-5p, hsa-miR18a#, hsa-miR-92a, hsa-miR-






















Basal-like 90 hsa-miR-136#, hsa-miR-497, hsa-miR-139-5p, hsa-miR-99a#, hsa-miR-145#, hsa-miR-195, hsa-miR-143, hsa-miR-145,
hsa-miR-335, hsa-miR-125b-2#, hsa-miR-139-3p, hsa-miR-7-2#, hsa-miR-216b, hsa-miR-487b, hsa-miR-100, hsa-miR-
410, hsa-miR-204, hsa-miR-376a, hsa-miR-99a, hsa-miR-337-3p, hsa-miR-27a#, hsa-miR-411, hsa-miR-656, hsa-miR-
495, hsa-miR-551b#, hsa-miR-770-5p, hsa-let-7b#, hsa-miR-378, hsa-miR-215, hsa-miR-127-3p, hsa-let-7c#, hsa-miR-





P values, < 0.01; maximal false discovery rate, 15%.
Figure 4 Comparison of normal breast samples with tumor samples. We identified 59 differentially expressed miRNAs between tumor
samples and normal breast samples. The median expression of these miRNAs is significantly elevated in normal breast samples, as illustrated by
the boxplot (A). The top four miRNAs (miR-215, miR-299-5p, miR-411, and miR-452) with the greatest difference between normal breast samples
and breast tumor samples by fold change are depicted in panels B through E. The corresponding false discovery rate is provided in top of each
boxplot. All miRNAs are significantly overexpressed in normal breast samples.
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selected miRNAs, respectively, which were analyzed by
using Ingenuity Pathway Analysis. For each miRNA, the
five most relevant networks with their most strongly
enriched molecular and cellular functions (P < 0.001)
are listed in Table 3. Comparative analysis of enrich-
ment patterns demonstrated that all miRNAs were
involved in the regulation of global oncogenic processes
like cell proliferation, cell death, and cellular movement.
Circulating miRNA expression
To evaluate which blood medium was best suited for
investigating miRNA expression, we extracted sRNA
molecules from serum, plasma, platelet-rich plasma,
whole blood, and PBMCs. A significant increase in
sRNA concentration was observed only when comparing
the results obtained in whole blood with the results
obtained in other media (Kruskal-Wallis, P < 0.001;
Tukey HSD post hoc, all P values < 0.001). Results are
shown in Additional file 4. As our aim was to measure
circulating, tumor-specific miRNA expression, we
decided not to perform subsequent analyses on platelet-
rich plasma, whole blood, or PBMCs because of the pos-
sible contamination of host-specific miRNA expression.
Given a slight, not significant, increase in sRNA concen-
tration in serum when compared with plasma (5.3 μg/
ml versus 4.2 μg/ml), in addition to a more-consistent
sRNA yield in serum (CVserum, 50.4%; CVplasma, 94.5%),
we decided to use serum to evaluate circulating miRNA
expression.
The expression of four miRNAs (miR-299-5p, miR-
215, miR-411, and miR-452) with the greatest fold-
change, when comparing normal breast tissue with
breast tumor samples, was analyzed in serum samples
from 75 patients with breast cancer and 20 healthy
volunteers. We observed higher expression values for all
investigated miRNAs, except for miR-452, in serum
from healthy volunteers. Significant (P < 0.05) values
were obtained for miR-299-5p and miR-411, whereas
trends (P < 0.10) were observed for miR-215 and miR-
452. Results are shown in Figure 5.
We next compared the expression levels of miR-215,
miR-299-5p, miR-411, and miR-452 in serum from
patients with metastatic breast cancer receiving treat-
ment (group B), patients with untreated metastatic
breast cancer (group C), and healthy volunteers. The
group of patients with localized breast cancer was not
included in this analysis because of low sample size (n =
4). Results are shown in Figure 5. Kruskal-Wallis testing
revealed significant (P < 0.05) between-group differences
for all miRNAs, except miR-452. Tukey HSD post hoc
testing revealed that the lowest expression values were
observed in patients with metastatic breast cancer,






miR-215 1 37 28 Tissue morphology, cell death, drug metabolism
2 20 19 Developmental disorder, gene expression, genetic disorder
3 20 19 Cellular movement, immune cell trafficking, skeletal and muscular system development and
function
4 14 15 RNA damage and repair, cell death, molecular transport
5 13 14 Genetic disorder, cellular assembly and organization, cellular function and maintenance
miR-299-
5p
1 35 29 Cell-to-cell signaling and interaction, cellular growth and proliferation, tumor morphology
2 24 23 Gene expression, cellular movement, lipid metabolism
3 13 16 Cellular assembly and organization, DNA replication, recombination, and repair, gene expression
4 13 16 Cell morphology, cellular development, protein synthesis
5 11 14 Cell death, renal necrosis/cell death, cellular compromise
miR-411 1 33 26 Cell death, cell-to-cell signaling and interaction, cell-mediated immune response
2 27 23 Cardiovascular system development and function, organ development, organismal
development
3 17 17 Gene expression, protein synthesis, antimicrobial response
4 14 15 Cell death, cellular growth and proliferation, cellular assembly and organization
5 11 13 Inflammatory response, dermatologic diseases and conditions, inflammatory disease
miR-452 1 31 32 Gene expression, cellular movement, cell death
2 27 30 Cell-to-cell signaling and interaction, connective tissue development and function, cell
morphology
3 25 29 Cellular growth and proliferation, inflammatory response, cell death
4 25 29 Cellular development, gene expression, nervous system development and function
5 25 29 Cellular growth and proliferation, cardiovascular disease, tissue morphology
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whereas expression levels returned to normal with
treatment.
Finally, we compared the expression levels of the cir-
culating miRNAs with clinicopathologic variables,
response to treatment evaluated by the RECIST-criteria,
presence of circulating tumor markers, and the presence
of circulating methylated markers. These analyses were
done for all samples except those derived from healthy
volunteers. Results are shown in Table 4. Overall, few
significant associations were observed. The expression
levels for three of four miRNAs (miR-215, miR-299-5p,
and miR-411) show a negative association with patient
age at diagnosis (all P values < 0.100). Interestingly, all
miRNAs have higher expression levels in serum from
patients with progressive disease under treatment and
for two of four miRNAs (miR-215 and miR-411); these
differences were significant (P < 0.050). No associations
between circulating miRNA expression and the presence
of CTCs were observed. For miR-215 and miR-452, we
observed positive associations (P < 0.05) between their
expression levels in serum and the number of methy-
lated genes (any combination of ESR1, APC, and
RASSF1A) detected in plasma.
Discussion
We attempted to identify a panel of deregulated miR-
NAs in breast cancer and investigated their potential as
biomarkers for the detection and staging of breast can-
cer by using blood-based testing. Before analyzing the
miRNA-expression data, we first evaluated the perfor-
mance of the PCR technology used throughout this
study. To reduce the technical variation in our data set,
we included only informative miRNAs assays (Ct values
smaller than 35 in at least 25% of the cases) with similar
PCR efficiencies and similar differences in Ct values
before and after preamplification. The boundaries for
PCR efficiency were defined as described in earlier stu-
dies [34], and the boundaries for preamplification
Figure 5 Comparison of the expression profiles of miR-215, miR-299-5p, miR-411, and miR-452 between serum samples from patients
with breast cancer and serum samples from healthy volunteers (A through D). The boxplots on panels E through H represent the
comparison of the expression profiles of the same miRNAs between serum samples from healthy volunteers and from patients with metastatic
breast cancer receiving and not receiving treatment. The P values indicating the significance of the difference are indicated on top of the
boxplots.
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efficiency were set alike. The expression data recorded
by the final set of 373 selected miRNAs proved to be
reproducible, and no between-array card difference was
observed. Moreover, we noticed an above-moderate
agreement between the qRT-PCR-based miRNA profiles
of 12 samples with the miRNA profiles measured by
using the nCounter Analysis System.
This is important for two reasons. First, the nCounter
Analysis System incorporates only one enzymatic step
(that is, a ligase treatment for attachment of the reporter
tags) in its workflow and is therefore less prone to tech-
nical bias than is the PCR-based protocol that incorpo-
rates three enzymatic steps.
A second reason for comparing the miRNA expression
profiles by using alternative profiling techniques is
related to the fact that good normalization procedures
for miRNA expression data are currently still lacking.
The qRT-PCR-based miRNA-expression data in this
study were normalized relative to the mean expression
value of all miRNAs per sample, as proposed by Mest-
dagh et al. [35]. However, we think that this normaliza-
tion procedure might have a major drawback because of
the role of DICER1, a miRNA-preprocessing enzyme, in
breast cancer. Recent reports have shown that the
expression of DICER1 is different across the different
molecular subtypes [14,40-42]. As DICER1 is involved
in cleaving the precursor miRNAs into mature miRNAs,
variation in DICER1 expression might result in altered
turnover rates of the precursor miRNAs and, hence,
higher concentrations of mature miRNAs in those
tumor samples with higher DICER1 expression. There-
fore, we reason that the mean miRNA-expression levels
Table 4 Associations between circulating miRNA expression and clinicopathologic variables
Group Variable Test MIR-215 MIR-299-5p MIR-411 MIR-452

















































































































































































































































































































































aA negative T-value indicates a higher expression in the “positive” group.
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can vary depending on DICER1 expression and that
normalization relative to the mean miRNA-expression
level might obscure between-sample differences, particu-
larly in breast cancer. The alternative approach would
be to use the reference miRNAs provided on the array
cards or miR-16, which is often suggested as reference
miRNA. However, the CVs for these reference miRNAs
were about threefold higher than the CV of the mean
miRNA expression level per sample. In addition, about
20% of the miRNA assays on both array cards yielded
more-robust expression data (data not shown).
Therefore, in spite of our previously raised concerns,
we decided to normalize our expression data relative to
the mean Ct value per sample and compare the results
with the data obtained by using nCounter Analysis Sys-
tem, which uses a panel of five mRNA assays (RPLPO,
RPL19, ACTB, B2M, and GAPDH) for data normaliza-
tion. The above-moderate agreement between the
miRNA-expression data obtained by using both profiling
techniques lends credit to the biologic validity of our
qRT-PCR-based miRNA-expression profiles.
Further evidence that the applied normalization proce-
dure did not obscure molecular subtype-specific differ-
ences is derived from the UHCA, which showed that
the molecular subtypes govern global themes in our
miRNA expression data set. Also, the miRNA-based
molecular subtype classification is in agreement with the
classification resulting from the application of a more-
validated algorithm on mRNA data (SSP) [37]. For
example, the comparison of the miRNA-based expres-
sion profile of SSP-defined Basal-like breast tumors with
the miRNA-based expression centroid for Basal-like
breast cancer results in more-elevated Spearman corre-
lation coefficients than when compared with the results
obtained for non-Basal-like breast tumor samples.
Although the classification error rate was substantial, we
must keep in mind that the miRNA-based expression
centroids reported by Blenkiron and colleagues [14] are
based on a limited series of samples. Therefore, it is
arguable that the expression centroids are not very
stable, which affects the classification accuracy. When
performing a supervised analysis, we were able to iden-
tify sets of specific miRNAs for each molecular subtype,
except for the ErbB2+ breast tumor samples. Overall,
our results are in line with previously reported data
[14,43-45], except for the results with respect to the
ErbB2+ subtype, for which an miRNA signature has
been defined in the past [45]. Of note is the concordant
overexpression of miRNAs belonging to the polycistro-
nic miR-17-92 cluster (miR-17, miR-18a, miR-19a, miR-
20a, and miR-92) and its paralogs (miR-18b and miR-
106a) in Basal-like breast tumors. The miR-17-92 cluster
is known to downregulate ERa in a MYC-dependent
manner and inhibits the protein translation of AIB1, an
ERa transcriptional coactivator [46]. Also, the miR-17-
92 cluster is known to regulate cell migration, invasion,
and metastasis in breast cancer by regulating ROCK
[47] and the HBP1/b-catenin pathway [48].
Although the sample-clustering pattern based on the
expression of 373 miRNAs demonstrated that the global
themes in our expression data set are related to the pre-
sence of the classic molecular subtypes in breast cancer,
we did identify one sample cluster without any connec-
tion to the classic molecular subtypes. This sample clus-
ter originated early in the dendrogram, indicative of a
specific miRNA-expression profile. Indeed, the heatmap
did reveal an miRNA cluster, including members of the
miR-200 family, members of the let-7 family, and
NFB-regulating miRNAs [49], that is overexpressed in
this group of tumor samples, at a level exceeding the
expression level observed in the Luminal-like sample
cluster. The latter observation is at least remarkable, as
all these miRNA families are known to inhibit stem cell-
specific pathways, epithelial-to-mesenchymal transition,
cell proliferation, and other global oncogenic processes
[16,50-53]. Hence, their overexpression would induce a
more-differentiated, less-proliferative, less-mesenchymal,
and less-migratory/invasive cell phenotype. The pre-
sence of this tumor sample cluster with its particular
molecular characteristics warrants further investigation.
When focusing on the Normal-like samples, a clear and
distinct miRNA profile was observed. In addition, the
true normal breast samples constituted a coherent
group inside the cluster of the Normal-like samples,
suggesting vast differences in miRNA expression
between tumor samples and normal breast samples.
Indeed, supervised analysis revealed high numbers of
differentially expressed miRNAs with nominal (uncor-
rected) P values less than 0.05.
The huge difference in miRNA expression between
normal and tumor samples underlines the important
role of miRNA deregulation in the development of
breast cancer. After correction for false discovery, we
observed that the majority of the differentially expressed
miRNAs have attenuated expression levels in the tumor
samples. The global repression of miRNAs in cancerous
tissue relative to normal tissue has been reported pre-
viously and suggests that most miRNAs have a tumor-
suppressive function [13]. This view is corroborated by
reports on the cellular functions of the top four (miR-
215, miR-299-5p, miR-411, and miR-452) differentially
expressed miRNAs by fold-change. Song et al. [54]
demonstrated that miR-215 overexpression in a colon
cancer cell line reduced the proliferation rate and led to
improved cell-cycle control, probably due to an
increased expression of the cell-cycle control genes p53
and p21. Duan et al. [55] showed that miR-299-5p
expression increased downstream of the tumor
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suppressor PRDM5 in HEK293 cells. In contrast, Fang et
al. [56] showed that SOX2, a gene with tumor-promot-
ing activity involved in cell proliferation and colony for-
mation of LN229 glioblastoma multiforme cells,
represses miR-452. The evidence for a role of miR-411
as tumor suppressor is less clear, but this miRNA is
located at the 14q32.31 locus, which is known to harbor
many tumor-suppressive miRNAs [57]. The biologic
processes regulated by miR-215, miR-299-5p, miR-411,
and miR-452, identified through the analysis of their
respective target-gene lists, are in line with their role in
maintaining cellular homeostasis.
Because of the marked overexpression of miR-215,
miR-299-5p, miR-411, and miR-452 in normal breast
samples, in addition to the fact that miRNAs have a
proven stability in blood samples [29], we hypothesized
that this panel of miRNAs might be suitable for the
detection of breast cancer by using blood-borne testing.
The reason for using serum samples for this purpose is
twofold. First, we argued that miRNA-expression pro-
files in whole blood, platelet-rich plasma, and PBMCs
would be dominated by host miRNA expression, and
therefore would be less suitable for the detection of
tumor-specific miRNA expression. Conversely, reports
have shown that miRNA expression is also detectable in
serum and plasma samples from healthy donors [58].
Second, we noticed a slightly higher and more consis-
tent sRNA yield in serum as compared with plasma.
When evaluating the relative expression profiles of miR-
215, miR-299-5p, miR-411, and miR-452 in serum sam-
ples from patients with breast cancer and healthy volun-
teers, we recorded comparable expression profiles in
tissue and blood samples, except for miR-452. Of note,
when comparing absolute CT values, the expression dif-
ferences between samples from patients with breast can-
cer and healthy volunteers were maintained, however, at
a higher fold-change level. In addition, we observed that
the reduction of miRNA expression was particularly
obvious in serum samples from patients with untreated
metastatic breast cancer, whereas the expression profiles
“normalized” with treatment.
No associations between blood-borne miRNA expres-
sion in serum samples from patients with breast cancer
and the classical clinicopathologic variables were
observed, except for the patient’s age at diagnosis. How-
ever, this should not be surprising, as our miRNA panel
was not selected to make this distinction. Of note is the
lack of associations between circulating miRNA expres-
sion and the presence of CTCs, measured by three alter-
native techniques. This observation suggests that
recorded serum miRNA profiles are not CTC derived
and that the mechanisms responsible for the release of
miRNAs in the circulation are unrelated to the extrava-
sation of tumor cells. Indeed, several reports have
suggested that miRNAs are selectively released in the
bloodstream by tumor cells either via exosomes or
attached to lipoprotein complexes or within a functional
RISC complex [59-63]. These mechanisms of secretion
offer an explanation for the marked stability of miRNAs
in the blood stream, due to shielding of the associated
miRNAs from RNAse-activity. In addition, miRNAs
secreted as such are functionally active and have been
found to regulate gene expression in target cells, thereby
providing alternative ways of cell-cell communication.
This opens the possibility that miRNAs, secreted by
tumor cells, evoke a response in host cells altering their
expression profile, which explains how subtle differences
in tumor-specific expression are measurable in a back-
ground of nontumorigenic expression. More specific in
the context of our results, one could envision that
tumor-driving miRNAs, secreted by tumor cells, affect
the expression profile of host cells, which is reflected in
the serum profile of breast cancer patients and explains
the observed decrease in miRNA expression.
Conclusions
The present data provide a technologically validated fra-
mework to elaborate on the study of miRNA-deregula-
tion in the development of breast cancer. We potentially
identified a novel subgroup of breast tumors with ele-
vated expression of tumor-suppressive miRNAs, and we
showed that miRNAs can be used as blood-borne bio-
markers for detection and staging of breast cancer. The
identification of several molecular subtype-specific miR-
NAs in this study also suggests that blood tests directed
at the molecular subtypes can be developed in the
future. However, to do so, a larger repository of molecu-
lar subtype-specific miRNA expression is required.
Additional material
Additional file 1: To evaluate assay reproducibility, we tested four
samples in duplicate. The scatterplots demonstrate the result for these
samples. The blue line represents the regression line and the correlation
coefficients, and corresponding P values are given on top of the
scatterplot.
Additional file 2: To perform a technical validation of our miRNA-
expression data, we analyzed 12 samples by using the nCounter
Analysis System and compared these results with the qRT-PCR-
based miRNA expression profiles. The scatterplots illustrate the result
of this comparison. The correlation coefficients for each comparison are
reported on top of the scatterplots.
Additional file 3: Boxplots showing the comparison of the miRNA-
expression profiles of four selected miRNAs (miR-135b, miR-106a,
miR-100, and miR-145) between tumor samples grouped by their
SSP-defined molecular subtype. The top row represents two miRNAs
overexpressed in the Basal-like samples; the bottom row represents two
miRNAs overexpressed in Normal-like samples. The color scheme under
each boxplot is adopted from the article by Blenkiron and colleagues
and depicts the expression of the corresponding miRNAs according to
the SSP-defined molecular subtypes, as reported in their study. Red
indicates overexpression, and grey indicates repression. As can be
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observed, the variation in miRNA expression across the SSP-defined
molecular subtypes is in good agreement in both studies.
Additional file 4: Boxplot illustrating the sRNA yields extracted from
five different peripheral blood media. The X-axis depicts the different
analyzed media (from left to right: serum, plasma, platelet-rich plasma,
peripheral blood mononuclear cells (PBMCs), and whole blood); the Y-
axis depicts the sRNA concentration. The sRNA yields are most
pronounced in whole blood followed by the PBMC fraction. For serum,
plasma, and platelet-rich plasma, the results are comparable, although
the sRNA yield is slightly higher in serum.
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criteria in solid tumors; RISC: RNA-induced silencing complex; sRNA: small
RNA; SSP: single sample predictor; UHCA: unsupervised hierarchical cluster
analysis.
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